64 - Global Clinical Trials & Coordination (S5E4)

You know, it's kind of a sobering thought when
you really stop and think about it. What's that?
For every 10 potential new medicines that actually
make it to clinical trials. Yeah. Only about
one actually gets through all those hoops and
hurdles and makes it to the people who desperately
need it. Yeah. That's a pretty huge failure rate,
right? It is a huge failure rate. When you think
about it. So right off the bat, you realize,
OK, developing new therapies, this is not a simple
thing. Not at all. And it gets even more complex
when you think about not just testing a drug
in one place, but what about coordinating those
studies across multiple countries? Different
regulations, different cultures, different everything.
Yeah, global drug development. That's the big
leagues. It is. Definitely. So this deep dive,
we're going to kind of tackle this fascinating.
and often surprisingly challenging world of global
clinical trials. I like it. This whole complex
dance of how do you run research in all these
different regions? And I know you're tuning in
because you want to really get a good handle
on this topic quickly and thoroughly. That's
what we're here for. And we've got some great
source material to work with today. Right. We've
got a transcript. that covers various aspects
of drug development, everything from the nitty
-gritty lab work to the regulatory hurdles. But
our real focus today is those specific hurdles
that pop up when you're doing trials on a multinational
scale. I'm intrigued. So think global clinical
trials. What are the challenges? Gotcha. Our
mission, if you will, is to really equip you
with a clear understanding of all those regulatory,
logistical, cultural obstacles. Right. that researchers
bump into when they're trying to bring these
promising new treatments to people worldwide.
That makes sense. Get ready, because there are
definitely some lightbulb moments coming your
way as we go through this. I think one of the
things that really struck me right off the bat,
looking at this material, is just how incredibly
collaborative drug development on a global scale
really is. Oh, absolutely. It's not like one
lone genius tinkering away in a lab and then
ta -da. No magic bullet. Yeah, there's no magic
bullet. It's a team effort. It's a huge network.
You've got scientists from all different fields.
Of course. You've got those super rigorous regulatory
bodies in all the different countries. Yes, and
I caught up. The pharmaceutical companies themselves
drive in the research. Uh -huh. And then, of
course, and maybe most importantly, the patients
who are actually volunteering. The heart of it
all. to be part of these trials. So as our sources
emphasize, it's really a human endeavor at its
core. I think that's a beautiful way to put it.
This drive to understand diseases, to ease suffering.
and to ultimately improve people's lives. Absolutely.
It's a shared goal that unites so many people
across borders and disciplines. It is, but it's
also a goal that has to navigate. Oh, yeah. What
often feels like a very intricate and often fragmented
global landscape. Yeah, it's a bit of a puzzle,
isn't it? It is. It's like a puzzle with a lot
of pieces that don't always fit together neatly.
Exactly. And I think a good place to start unraveling
that puzzle is to look at the regulatory side
of things. OK, regulation. Because let's face
it. Every country wants to make sure that any
new medicine being tested within its borders
is safe and effective for its citizens. So naturally,
each country has its own set of rules and regulations
and procedures. And so how do researchers even
begin to untangle? that whole web of regulations.
Well, it's tricky, but that's where the concept
of harmonization comes in. OK, harmonization.
So while each nation has its own regulatory authority,
like the FDA here in the US or the European Medicines
Agency in Europe, there's also this recognition
that we need some level of global consistency
to streamline the process of drug development.
That makes sense. So that's where organizations
like the International Council for Harmonization
or ICH come into play. Yeah, ICH. Yeah, they
work to establish international guidelines for
various aspects of drug development. OK, so give
me an example of what kind of guidelines are
we talking about. Well, everything from how clinical
trials are designed and conducted to how the
data is collected, analyzed, and reported. So
it's almost like they're trying to create this
internationally agreed upon set of best practices.
Yeah that's a good way to put it. It's about
establishing a common language and framework.
So researchers in different countries can work
more efficiently together. Okay so the ICH is
creating this sort of overarching framework.
Yeah. But I'm guessing it's not as simple as
just following the ICH guidelines and you're
good to go worldwide. You're right. It's not
quite that simple. OK. Because even with these
international guidelines in place, researchers
still have to meticulously comply with the specific
local regulations of each country where they're
conducting their clinical trial. Right. So it's
like this dual regulatory landscape. Yeah. Exactly.
You've got the global guidance from the ICH,
but then you've also got the very specific requirements
of each individual country. Which could be a
lot to keep track of. It definitely can be, and
it often adds significant time and cost to the
whole drug development process. Because I imagine
you're basically going through a whole new approval
process. You got it. In every single country.
Pretty much. And that can sometimes add years
to the timeline for bringing a new medicine to
market. Wow, so it's not just about the science.
No, it's a delicate dance between science and
regulation. It is. It's this balancing act between
wanting to make sure that these drugs are safe
and effective in every population. Right. But
also trying to get them to the people who need
them. Yeah, it's a complex challenge. As quickly
as possible. Absolutely. It is. All right, so
you've jumped through all the regulatory hoops.
Right. You've got your approvals. You're ready
to go. Mm -hmm. But then you actually have to
run a multinational trial, which just the logistics
of that blow my mind a little bit. It's a massive
undertaking coordinating research sites across
different time zones, different languages, different
cultures. Where do you even begin to organize
something that big? Well, you need a really,
really good plan. OK. and impeccable communication
is absolutely paramount. Right, because you've
got research teams all over the world. Exactly.
Each one operating on a different schedule and
potentially speaking different languages. So
how do you make sure everybody is on the same
page? It's a combination of things. You need
clear protocols, regular meetings, video conferencing,
and often a dedicated team. whose sole job is
to manage the logistics of the trial. Like a
global project management team. Exactly, and
then on top of that you have the practical challenges
of shipping things internationally. Right, like
the actual drugs? Yes, the investigational drugs
themselves and biological samples. like blood
or tissue samples. So it's not just like sending
a package through the mail? Not even close. You
need a detailed documentation. To comply with
all the import and export regulations, you have
to ensure proper labeling and identification
at every single site. So no mix -ups. Exactly.
And you need to think about temperature control.
Oh, right. Because some of those drugs can be
pretty sensitive. Absolutely. Some drugs have
to be kept at very specific temperatures throughout
the entire journey, or they degrade. So you can't
just toss a vial of some experimental medicine
in a box. You can. And hope for the best. And
hope it makes it halfway across the world intact.
Exactly. You need specialized packaging and shipping
procedures to maintain the integrity of those
drugs. It's a whole science in itself. And one
of the sources even mentions that just the storage
of the drug ingredients needs to be carefully
considered too. Oh, absolutely. You have to think
about environmental factors like temperature,
humidity, light exposure. To make sure those
ingredients stay stable. Yeah, all of that can
affect the quality and efficacy of the final
drug product. Right, so it's like this chain
of custody that has to be maintained at every
step of the way. From the moment the ingredients
are manufactured to the moment the drug is administered
to a patient in the trial. And speaking of manufacturing,
what about the actual production of the drugs
that are being used in these trials? That's another
huge piece of the puzzle. Because now you're
potentially talking about multiple manufacturing
locations. Often in different countries with
different standards. And so how do you ensure
that the quality of the drug is consistent? Well,
that's where good manufacturing practices or
GMPs become absolutely critical. Okay. GMPs.
GMPs are essentially a set of guidelines. that
ensure drugs are consistently produced and controlled
according to very strict quality standards. So
it's kind of like a global quality control standard
for pharmaceuticals. Exactly. And these standards
cover everything from the facilities themselves
to the equipment, the personnel, the processes.
So it's not just about making sure the drug is
made correctly. No, it's about ensuring that
every step of the manufacturing process is controlled
and documented. So there's no room for error?
Ideally, no room for error because you want to
minimize any risk that could compromise the safety
and efficacy of the final product. Right, which
is even more important when you're talking about
a drug that's being tested in a clinical trial.
Absolutely, because you're dealing with human
lives. Exactly. And so far, we've talked about
regulations. We've talked about logistics. We
talked about manufacturing. Right. But then there's
this whole other layer. Oh, yes. Which is the
human element. The most important element. I
think the cultural and ethical considerations
of conducting trials in different parts of the
world. And that's a conversation we definitely
need to have. It is, because it's one thing to
follow the regulations, but it's another thing
entirely to actually work with people. Especially
when those people come from diverse cultural
backgrounds. Right. And so how do you ensure
that you're conducting these trials ethically?
Well, first and foremost, ethical conduct has
to be the foundation of all clinical research.
Absolutely. And this becomes even more critical
when you're working across different cultures
with different values and beliefs. Because of
what might be considered ethical in one culture.
Right. might not be in another. Exactly. So researchers
have to be extremely sensitive to these differences.
And so how do they navigate that? Well, in each
country where a trial is being conducted, you
have to get approval from a local ethics committee
or institutional review board. Sometimes called
an IRB. Right, an IRB. And these local bodies,
they're responsible for making sure that the
trial is ethically sound and culturally appropriate.
So it's not just a rubber stamp? Not at all.
They carefully review the trial protocol, the
informed consent documents, and they consider
the potential risks and benefits to the participants.
And imagine one of the biggest challenges in
global trials is obtaining truly informed consent.
Absolutely, because you have to make sure that
the participants really understand what they're
signing up for. Right, and that they're not being
coerced or pressured in any way. Exactly. And
this becomes even more complicated when you're
dealing with different languages and different
cultural norms around medical decision -making.
Right, because in some cultures, for example,
the decision to participate in a medical trial
might involve the entire family. Right. It's
not just an individual decision. And so researchers
have to be aware of and respect. those cultural
dynamics. Absolutely. They have to be very careful
to ensure that consent is truly voluntary and
informed. And then on top of all of that, there's
this really critical aspect of global trials
that I think we need to discuss. Let's do it.
Which is the importance of diversity. Diversity
in clinical trials. Yes. Both in terms of including
different populations and really understanding
the role of genetic diversity in how drugs work.
It's incredibly important. Why is that so vital?
Well, because people are different. We have different
genetic makeups, different lifestyles, different
environments. And all of that can affect how
our bodies respond to medication. Exactly. And
historically, clinical trials have often been
criticized for not being representative of the
real world. Okay, how so? Well, they've often
overrepresented certain groups, like white men,
for example, and underrepresented other groups.
That's women and people of color. Exactly, and
that's a problem because it means that we might
not be getting a complete picture of how a drug
will work in different populations. So if you
only test a drug in a very narrow slice of the
population, you might miss some really important...
safety issues. Absolutely. Or differences in
how affected the drug is. And that's why there's
this increasing focus now on including more diverse
populations in clinical trials. So tell me more
about that. What does that actually look like
in practice? Well it means actively recruiting
participants from different ethnic groups. different
age groups, different genders, different socioeconomic
backgrounds. So you're trying to get a much broader
representation of humanity. Exactly, because
the goal is to ensure that the medicines we develop
are safe and effective for everyone who needs
them. And this also brings up the issue of genetic
diversity. Right, because genetic variations
can have a huge impact on how our bodies process
drugs. So can you break that down for me a little
bit? Sure. So our genes influence everything
from how our bodies metabolize drugs to how those
drugs interact with their targets in the body.
And so a drug that might work really well in
one person? Might not work as well, or could
even be harmful in someone else. Exactly. And
that's why understanding genetic diversity is
so crucial for developing safe and effective
medications. And the source material mentions
something called enrichment strategies. Oh yes,
enrichment strategies are becoming increasingly
common in clinical trials. So what are those?
So enrichment strategies involve selecting participants
based on specific characteristics, like certain
genetic markers or the presence of a particular
disease subtype. And why do they do that? Well,
the idea is to increase the likelihood of seeing
a drug effect by focusing on the patients who
are most likely to benefit from the treatment.
So it's kind of like narrowing the focus of the
trial. Exactly. And it can be very useful for
proving that a drug works and for understanding
its mechanism of action. But are there any downsides
to this approach? Well, one potential downside
is that it can limit the generalizability of
the findings. OK, what do you mean by that? So
if you only test a drug in a very specific subset
of patients, it's harder to know for sure how
it will work in the broader population. Right,
because the people in the trial might not be
representative of everyone. Exactly. And that's
why regulatory agencies often require something
called post -market surveillance. After a drug
has been approved. Exactly. So even after a drug
is on the market, they continue to collect data
to see how it's working in the real world. In
a more diverse group of people. Exactly. And
this helps to identify any potential safety issues
or differences in efficacy that might not have
shown up in the original trials. So it's kind
of like an ongoing safety check. Exactly. It's
an important part of ensuring that new medicines
are both safe and effective. For everyone who
needs them. Precisely. And you know, one of the
things that I found really fascinating in the
source material. was the discussion of how technology
and artificial intelligence are playing an increasingly
important role in global clinical trials. Oh
yeah, let's talk about that. Because when you're
dealing with such massive amounts of data coming
in from all over the world, technology is essential
for managing all of that information. So what
kind of technology are we talking about here?
Well, things like electronic data capture systems,
which allow researchers to collect and store
data electronically instead of using paper forms.
Right, which would be a nightmare. A total nightmare.
And then you have cloud -based platforms that
enable real -time communication and collaboration
among research teams. So no matter where they
are in the world. Exactly. They can all access
the same data. and communicate with each other
easily. And these platforms can also help with
things like language translation. Absolutely,
which is crucial for global trials where people
might be speaking different languages. And then
on top of that, you have artificial intelligence
or AI. Which is being used to analyze this vast
amount of data. and identify patterns. So it's
like AI is helping us to see things. Exactly.
That we might not be able to see with the naked
eye. It can help us to identify potential safety
signals to predict which patients are most likely
to respond to a treatment. So it's kind of like
AI is helping us to personalize medicine. Yeah,
in a way, it's allowing us to tailor treatments
to individual patients based on their unique
characteristics. Which is pretty amazing when
you think about it. It is. It's really revolutionizing
the way we develop and deliver health care. And
one of the things that I found really fascinating
in the source material was this idea that even
seemingly small details in the drug development
process can have huge ripple effects down the
line. Oh, absolutely. They gave this example
of how the material of a reactor in a manufacturing
plant actually ended up affecting the purity
of a drug. It's amazing how something so seemingly
insignificant can have such a big impact. It
really underscores just how meticulous you have
to be at every step of the process. Absolutely.
Precision and attention to detail are paramount.
And another thing that really struck me was the
discussion of bioavailability. Ah, yes, bioavailability.
That's a crucial concept in drug development.
So for our listeners who might not be familiar
with that term. Of course. Can you explain what
it means? Sure. So bioavailability essentially
refers to how much of the drug that you take
actually gets into your bloodstream. OK. And
becomes available to have an effect. Right. Because
you could take a pill, but if the drug doesn't
actually get absorbed into your body, it's not
going to do anything. Exactly. So bioavailability
is a really important factor in determining the
effectiveness of a drug. And the source material
emphasizes that when you're running global trials,
you have to be really careful. to use standardized
procedures. For measuring bioavailability. Yeah,
because otherwise you're comparing apples to
oranges. Exactly. You can't have one research
site using one method and another site using
a different method. And then trying to combine
that data. It just won't be reliable. So standardization
is key. Absolutely. It's essential for ensuring
that the data you're collecting from different
sites is actually comparable. And another challenge
that was mentioned in the source material was
the issue of drug solubility. and permeability.
Ah, yes. Those are two key factors that can affect
how a drug is absorbed and distributed in the
body. Can you break those down for us? Sure.
So solubility refers to how well a drug dissolves
in fluids, like your stomach fluids or your blood.
And permeability refers to how easily the drug
can pass through cell membranes to reach its
target in the body. And so how do those factors
play into global clinical trials? Well, certain
drugs might have solubility or permeability issues
that make it difficult to develop a formulation
that's effective in all populations. So give
me an example. Sure. So some drugs might dissolve
really easily. OK. but then they have trouble
getting absorbed into the bloodstream, or they
might be absorbed well, but then they get broken
down too quickly by the liver. So they're not
active long enough. Exactly. And these kinds
of challenges can be even more pronounced in
global trials where you're dealing with different
diets, different genetics, different environmental
factors. Right. So something that works well
in one population might not work as well in another.
And that's why drug formulation is such an important
part of the drug development process. And it's
not just about getting the drug into a pill or
a capsule. No, it's about creating a formulation
that will deliver the drug to the right place
in the body, at the right concentration, and
for the right amount of time. It's like this
delicate balancing act. It is, and it requires
a deep understanding of both the drug itself
and the human body. And, you know, as we've been
talking about all these complexities, I can't
help but think about the sheer amount of data
that must be generated from all these global
trials. Yeah, we're talking about mountains of
data. And how do you even begin to make sense
of all that information? Well, that's where technology
comes in again. We talked about data management
systems and cloud -based platforms. But there
are also sophisticated data analysis tools that
can help researchers to sift through all that
data and extract meaningful insights. So it's
not just about collecting the data. No, it's
about making sense of it. And turning it into
knowledge. Exactly. And this is where things
like biostatistics and bioinformatics come in.
These are specialized fields that use statistical
and computational methods to analyze biological
data. So it's like you need a whole team of experts
just to handle the data. From statisticians to
computer scientists to data visualization experts.
Right, because you need to be able to see the
patterns in the data. Yeah, you need to be able
to tell the story of the data. And I imagine
that this is another area where AI is starting
to play a role. Oh, absolutely. AI is being used
to automate some of the data analysis tasks and
to identify patterns that human might miss. So
it's like AI is augmenting the capabilities of
the human researchers. Exactly. It's helping
us to analyze data more efficiently and accurately.
And to make better decisions about drug development.
Precisely. It's a really exciting time to be
working in this field. So as we wrap up this
deep dive into the complexities of global clinical
trials, what are some of the key takeaways that
you think our listeners should really walk away
with? Well, I think one of the biggest takeaways
is that global drug development is a truly collaborative
effort. Yeah, we talked about that at the beginning.
It requires the expertise of scientists, clinicians,
regulators, ethicists. statisticians, in patients,
and of course the patients themselves. It really
is a global endeavor. It is and another key takeaway
is that it's incredibly complex. Yeah, we've
covered a lot of ground today. There are so many
factors to consider. From the science, to the
regulations, to the logistics, to the culture,
and those seemingly small details. Right. That
can make all the difference. Like the material
of that reactor. Yeah, exactly. Or the specific
method for measuring bioavailability. It's all
connected. It is and I think another important
takeaway is that this complexity is the reason
why drug development takes so long and why it's
so expensive. It's not just about discovering
a new molecule in the lab. No, it's about making
sure that that molecule is safe and effective
for all the different people who might need it.
And that takes time and resources. Absolutely,
but it's an investment worth making. Because
ultimately it's about improving human health.
Exactly. It's about finding new treatments for
diseases that cause suffering and extending human
life and improving the quality of that life.
And for me, the biggest light bulb moment was
really understanding the importance of diversity
in clinical trials. Yes. Both in terms of the
participants themselves and in terms of the researchers.
Right. Because different perspectives lead to
better science. Exactly. And I think that's a
perfect note to end on. I agree. So here's a
final thought for you to consider. As the world
becomes increasingly interconnected, how can
we make global clinical trials even more efficient
and collaborative while still upholding the highest
ethical standards and ensuring that the benefits
of these new treatments reach all populations
equitably? It's a big question. It's a question
that researchers and policymakers are grappling
with right now. And it's a question that we'll
continue to explore. On future deep dives. I
look forward to it. Thanks for joining us. It's
been a pleasure. And until next time, keep learning.